hydration effects glp-1 receptor agonists weight loss Impact of GLP- 1 Agonist Therapy in Patients High Risk for Sarcopenia | Current Nutrition Reports GLP-1 weight loss drugs leave
Description
2017;66:A315A315315
P =0.022), and all-cause mortality (HR 0.64, 95% CI 0.57 0.72
Pharmaceutical companies do not sell these drugs branded for obesity in lower income countries and sell these obesity drugs in only a small number of higher income countries
Front Immunol (2022) 13:967151
Some may be especially useful for patients with steatohepatitis or other metabolic comorbidities
Sumithran P, Prendergast LA, Delbridge E, et al
